RELATED PARTY TRANSACTIONS (Details) |
3 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Mar. 12, 2025
$ / shares
shares
|
Mar. 05, 2025
item
$ / shares
|
Dec. 01, 2023
USD ($)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
Aug. 31, 2024
$ / shares
|
|
| RELATED PARTY TRANSACTIONS | |||||||||
| Research and development expense | $ 692,000 | $ 704,000 | $ 1,918,000 | $ 1,677,000 | |||||
| Current liability | 5,338,000 | 5,338,000 | $ 3,465,000 | ||||||
| Converted into units | shares | 1 | ||||||||
| Exercise price | $ / shares | $ 2.25 | $ 2.25 | $ 1.25 | ||||||
| Number of representatives nominated by purchaser | item | 3 | ||||||||
| Date of the Amendment | item | 3 | ||||||||
| Threshold Condition | 1 year | ||||||||
| Percentage of warrants held by purchasers | 50.00% | ||||||||
| Number of directors | item | 2 | ||||||||
| Biodesix Inc | |||||||||
| RELATED PARTY TRANSACTIONS | |||||||||
| Ownership percentage | 10.00% | ||||||||
| Biodesix Agreement | |||||||||
| RELATED PARTY TRANSACTIONS | |||||||||
| Research and development expense | $ 125,000 | ||||||||
| Current liability | $ 0 | $ 0 | |||||||
| Biodesix Agreement | Biodesix Inc | |||||||||
| RELATED PARTY TRANSACTIONS | |||||||||
| Ownership percentage | 5.00% | ||||||||
| X | ||||||||||
- Definition The number of directors appointed from the representatives nominated by the purchasers. No definition available.
|
| X | ||||||||||
- Definition The number of representatives nominated to the Board of Directors by the purchasers. No definition available.
|
| X | ||||||||||
- Definition Percentage of warrants held by purchasers to nominate representatives for the board of directors. No definition available.
|
| X | ||||||||||
- Definition The period for nominating representatives from the date of amendment. No definition available.
|
| X | ||||||||||
- Definition The period for nominating representatives from the date of listing in National Securities Exchange. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|